Target intelligence / Profile preview

60S ribosomal protein L7 (RPL7)

Target
RPL7
Molecular classification
Ribosomal protein, Structural protein, Other
01

Overview

60S ribosomal protein L7 (RPL7) is a conserved structural protein of the large (60S) ribosomal subunit in eukaryotic cells, encoded by the RPL7 gene[1][3][5]. It binds RNA—including G-rich regions of 28S rRNA and various mRNAs—and contains an N-terminal basic region-leucine zipper (BZIP)-like domain enabling homodimerization, stable DNA and RNA binding, and potential regulatory functions in translation[1][4][5]. RPL7 also supports ribosome association with the endoplasmic reticulum, and evidence suggests it mediates cellular co-factor activity during HIV-1 viral assembly via direct interaction with the Gag protein[3]. As an autoantigen, RPL7 is implicated in systemic autoimmune diseases, including systemic lupus erythematosus[1][5]. Disruption of RPL7 function may contribute to oncogenic processes, but this remains under investigation[3]. There are no approved drugs targeting RPL7, and its essential role in protein synthesis means it is not considered a classical therapeutic target[1][5].

Other names
Large ribosomal subunit protein uL30RPL7L7humL7-1uL3060S ribosomal protein L7
02

Biological functions

Structural constituent of ribosomeRNA bindingDNA bindingProtein bindingProtein homodimerizationInhibition of cell-free translationAutoantigen in systemic autoimmune diseaseRegulation of translation apparatusRibosome-ER association
03

Disease associations

Autoimmunity (Systemic lupus erythematosus)Cancer (potential role suggested by thyroid carcinoma core sub-network involvement)Other
04

Safety considerations

Autoimmunity risk due to autoantigenicityEssential for general protein synthesis—direct inhibition would risk cytotoxicity
05

Biomarkers

Autoantigen in systemic lupus erythematosus (used as biomarker in autoimmune diagnostics)

Beyond the preview

Go deeper on 60S ribosomal protein L7 (RPL7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60S ribosomal protein L7 (RPL7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call